Skip to main content
CABLIVI (caplacizumab-yhdp) logo
hero

The Capla 1000+ Project


Results from Phase 3 Pivotal Study: HERCULES2,3

Real-world evidence supports CABLIVI® (caplacizumab‑yhdp) early use in over 1000 patients with aTTP/iTTP1

The Capla 1000+ Project is an unprecedented, independent, retrospective cohort study reporting on the largest international series of patients with aTTP/iTTP treated with CABLIVI (n=1015).1

The Capla 1000+ Project study design1

Study findings: Early CABLIVI use upon diagnosis and decision to start PEX

Findings from the Capla 1000+ Project “strongly argue for the systematic use of CABLIVI early in the management of aTTP/iTTP, typically as soon as the diagnosis and decision to start PEX is made, to prevent the formation of deleterious microthrombi and potentially prevent adverse outcomes.”1 
—Investigators for the Capla 1000+ Project

Primary endpoint

3-month survival rate in CABLIVI group compared with control group1#

graph

Due to the limitations of this study's retrospective, multicenter, real-world analysis design, the findings represent associations and should not be interpreted as establishing causality.

3-month mortality rate was 4.2-fold higher in controls vs the CABLIVI group (95% CI: 2.22-7.7), regardless of rituximab use.

Early vs delayed use

Time to clinical response in early CABLIVI group compared with control group1**

graph

Due to the limitations of this study's retrospective, multicenter, real-world analysis design, the findings represent associations and should not be interpreted as establishing causality.

Median time to clinical response in the early CABLIVI group was 5 days (4-8) vs 6 days (4-12) in the control group.

Improved prognosis

Exacerbation rate, refractoriness, and number of PEX to achieve clinical response in CABLIVI group compared with control group1††,‡‡

graph

Due to the limitations of this study's retrospective, multicenter, real-world analysis design, the findings represent associations and should not be interpreted as establishing causality.

icon

Exacerbations

Exacerbations were less frequent with CABLIVI vs the control group

icon

Refractoriness

Patients receiving CABLIVI experienced less-frequent refractoriness vs the control group (1% vs 10.1%)

icon

Number of PEX

The CABLIVI group required fewer plasma exchanges to achieve clinical response (5 [4-8] vs 7 [4-16]), leading to an observed reduction in burden of care

#Death in the CABLIVI group (n=15/1015) was considered as directly related to uncontrolled aTTP/iTTP in 8 cases (53%); in 4 others, death resulted from aTTP/iTTP-related comorbidities, including 1 case of fatal intracerebral hemorrhage late in the management, while aTTP/iTTP was in clinical response; in the 3 remaining patients, death was not related to aTTP/iTTP. In the control group, death was directly related to uncontrolled aTTP/iTTP in all 26 patients with available data.
**In patients with delayed CABLIVI initiation, clinical response was obtained after a median of 4 days from CABLIVI initiation.
††Refractoriness was defined as persistent thrombocytopenia (considered severe if no doubling of baseline platelet count or platelet count <30x109/L; usually needs salvage therapy) by 4 days of standard treatment, together with persistently elevated LDH levels.
‡‡Exacerbation was defined as reappearance of thrombocytopenia, with or without clinical evidence of new ischemic organ injury within 30 days of stopping PEX or CABLIVI, with need to restart treatment.

Safety

Adverse events related to CABLIVI1

table

§§Data are missing for 2 patients. 
||||24 patients experienced 2 adverse events.

Hear what lead investigator Dr Paul Coppo has to say about the Capla 1000+ Project

Review the Capla 1000+ Project full publication

icon

The CABLIVI dosing regimen starts in the hospital and continues at home

Hand holding gear symbol

Enroll your patients in HemAssist™ Sanofi Support

ADAMTS13=a disintegrin and metalloproteinase with a thrombospondin type 1 motif, 13; aTTP/iTTP=acquired/immune-mediated thrombotic thrombocytopenic purpura; HR=hazard ratio; LDH=lactate dehydrogenase; PEX=plasma exchange; TE=thromboembolic; TPE=therapeutic plasma exchange; ULN=upper limit of normal.

INDICATION

CABLIVI (caplacizumab-yhdp) is indicated for the treatment of adult and pediatric patients 12 years of age and older with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS: 
CABLIVI is contraindicated in patients with previous severe hypersensitivity reaction to caplacizumab-yhdp or to any of its excipients. Hypersensitivity reactions have included urticaria.

WARNINGS AND PRECAUTIONS:
Hemorrhage:

  • CABLIVI increases the risk of bleeding. In clinical studies, severe bleeding adverse reactions of epistaxis, gingival bleeding, upper gastrointestinal hemorrhage, and metrorrhagia were each reported in 1% of subjects. Overall, bleeding events occurred in approximately 58% of patients on CABLIVI versus 43% of patients on placebo.
  • In the postmarketing setting cases of life-threatening and fatal bleeding were reported in patients receiving CABLIVI.
  • The risk of bleeding is increased in patients with underlying coagulopathies (e.g. hemophilia, other coagulation factor deficiencies). It is also increased with concomitant use of CABLIVI with drugs affecting hemostasis and coagulation.
  • Avoid concomitant use of CABLIVI with antiplatelet agents, thrombolytic drugs, heparin or anticoagulants. If clinically significant bleeding occurs, interrupt use of CABLIVI. Von Willebrand factor concentrate may be administered to rapidly correct hemostasis. If CABLIVI is restarted, monitor closely for signs of bleeding.
  • Withhold CABLIVI for 7 days prior to elective surgery, dental procedures or other invasive interventions. If emergency surgery is needed, the use of von Willebrand factor concentrate may be considered to correct hemostasis. After the risk of surgical bleeding has resolved, and CABLIVI is resumed, monitor closely for signs of bleeding.

ADVERSE REACTIONS:
In adults, the most common adverse reactions (>15% of patients) are epistaxis, headache, and gingival bleeding. In pediatric patients, the most frequently reported adverse reactions are epistaxis and tachycardia.

DRUG INTERACTIONS:
Concomitant use of CABLIVI with any anticoagulant or antiplatelet agent may increase the risk of bleeding. Avoid concomitant use when possible. Assess and monitor closely for bleeding with concomitant use.

PREGNANCY:
There are no available data on CABLIVI use in pregnant women to inform a drug associated risk of major birth defects and miscarriage.

  • Fetal/neonatal adverse reactions: CABLIVI may increase the risk of bleeding in the fetus and neonate. Monitor neonates for bleeding.
  • Maternal adverse reactions: All patients receiving CABLIVI, including pregnant women, are at risk for bleeding. Pregnant women receiving CABLIVI should be carefully monitored for evidence of excessive bleeding.

INDICATION

IMPORTANT SAFETY INFORMATION

References: 1. Coppo P, Bubenheim M, Benhamou Y, et al. Caplacizumab use in immune-mediated thrombotic thrombocytopenic purpura: an international multicentre retrospective cohort study (the Capla 1000+ project). Lancet. 2025;82:1-13 and suppl. doi:10.1016/j.eclinm.2025.103168 2. CABLIVI. Prescribing information. Sanofi. 3. Scully M, Cataland SR, Peyvandi F, et al; HERCULES Investigators. Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura. N Engl J Med. 2019;380(4):335-346 and suppl/protocol. doi:10.1056/ NEJMoa1806311 4. Rituxan® (rituximab). Prescribing information. Genentech, Inc.

© 2026 Sanofi. All rights reserved. CABLIVI, HemAssist, and Sanofi are trademarks of Sanofi or an affiliate. All other trademarks are the property of their respective owners. MAT-US-2513556-v1.0-01/2026 Last Updated: January 2026.